Diclofenac and 2-anilinophenylacetate degradation by combined activity of biogenic manganese oxides and silver

about

The key role of biogenic manganese oxides in enhanced removal of highly recalcitrant 1,2,4-triazole from bio-treated chemical industrial wastewater.Potential of the strain Raoultella sp. KDF8 for removal of analgesics.

P2860

Q46405582-29D66575-F89E-417F-B43D-F97077D4D56D Q50061402-F56EDF38-C82E-49D6-B430-F47022289679

P2860

Diclofenac and 2-anilinophenylacetate degradation by combined activity of biogenic manganese oxides and silver

Item

http://www.wikidata.org/entity/Q41840077

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Diclofenac and 2-anilinophenyl ...... ic manganese oxides and silver

@en

type

Item

label

Diclofenac and 2-anilinophenyl ...... ic manganese oxides and silver

@en

prefLabel

Diclofenac and 2-anilinophenyl ...... ic manganese oxides and silver

@en

P1476

Diclofenac and 2-anilinophenyl ...... ic manganese oxides and silver

@en

P2093

Francis Meerburg

http://www.w3.org/2001/XMLSchema#string

Tom Hennebel

http://www.w3.org/2001/XMLSchema#string

P2860

Energy conservation in chemotrophic anaerobic bacteria

Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research

The bactericidal effect of silver nanoparticles

Transformation of diclofenac by the indigenous microflora of river sediments and identification of a major intermediate.

The disruption of bacterial membrane integrity through ROS generation induced by nanohybrids of silver and clay.

Evidence for the presence of Mn(III) intermediates in the bacterial oxidation of Mn(II).

Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?

Removal of endocrine-disrupting chemicals in activated sludge treatment works.

Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles.

Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water.

P304

388-395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1751-7915.2011.00323.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Willy Verstraete

Lynn Vanhaecke

Nico Boon

P577

2012-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221936773

http://www.w3.org/2001/XMLSchema#string

P698

22221449

http://www.w3.org/2001/XMLSchema#string

P921

diclofenac

P932

3821681

http://www.w3.org/2001/XMLSchema#string

Diclofenac and 2-anilinophenylacetate degradation by combined activity of biogenic manganese oxides and silver

about

P2860

P2860

Diclofenac and 2-anilinophenylacetate degradation by combined activity of biogenic manganese oxides and silver

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932